Aier Eye Hospital: Net Goodwill Equals 43% of Book Equity, Adjusted Profit Grew 1.36% in 2025, and CNY8.71 Leaves No Conservative Margin of Safety

My best estimate is that underlying domestic organic revenue growth is currently in the low- to mid-single digits, rather than the consolidated headline suggesting a return to historical high growth. That is an inference, not a disclosed metric. Domestic revenue grew 5.11% in 2025, while Aier continued absorbing hospitals bought in prior periods. Overseas revenue grew 16.47%, but the overseas perimeter has also expanded through acquisitions. The 39 institutions announced for purchase in December 2025 produced CNY 587.83m of revenue during the first nine months of 2025. Annualized, that is about CNY 784m. If, purely as an upper-bound thought experiment, all that revenue had been consolidated for a full comparable Q1, roughly CNY 196m of quarterly revenue would represent more than half of Aier’s CNY 370m Q1 2026 year-on-year revenue increase; the residual growth would be about 2.9%. Actual consolidation timing makes that calculation deliberately conservative, but it illustrates why reported growth cannot be assumed to equal like-for-like growth.

The reported growth rate is therefore a less useful KPI than the return Aier earns after paying to bring incubated hospitals onto the listed balance sheet.

The December 2025 transaction is the cleanest test. Aier agreed to pay CNY 963.02m for controlling stakes of 51%–100% in 39 institutions. The appraisers valued 100% of the targets’ equity at CNY 1.403bn. The targets collectively had CNY 685.90m of 2024 revenue and lost CNY 59.00m; during the first nine months of 2025 they generated CNY 587.83m of revenue and CNY 20.25m of profit. The targets were thus genuinely improving, but their annualized 2025 nine-month profit was only about CNY 27.0m. On the appraised full-equity value, that equals about 52 times annualized current earnings.

The simple calculation often quoted in secondary coverage—CNY 963m divided by CNY 27m, or roughly 36 times—is economically incomplete because CNY 963m buys only the acquired stakes, whereas CNY 27m is 100% of target profit. The cleaner aggregate comparison is CNY 1.403bn of full-equity value against CNY 27m of annualized full-company profit. The company itself emphasizes price-to-sales rather than current P/E: its disclosed overall transaction P/S was 2.05 times, below the 2.58 times median of the medical-service transactions it selected as comparables.

For that purchase to earn a 10% after-tax earnings return on CNY 1.403bn, the target cohort eventually needs around CNY 140m of annual net profit, more than five times its annualized nine-month 2025 run rate. An 8% return requires about CNY 112m, more than four times current annualized earnings. At the annualized 2025 nine-month revenue run rate, the cohort’s net margin was only about 3.4%. Even a 15% margin on that revenue would produce about CNY 118m of profit, or an 8.4% return on appraised equity value. A more satisfactory 10% return therefore needs both revenue growth and substantial margin maturation. These are my calculations from the transaction disclosure.

That would be less concerning if goodwill were small. It is not. At year-end 2025, gross goodwill was CNY 11.366bn. The accumulated impairment reserve was about CNY 1.879bn, leaving approximately CNY 9.486bn net goodwill. Net goodwill was 25.9% of CNY 36.676bn total assets; gross goodwill was 31.0%. During 2025 alone, gross goodwill additions from business combinations were CNY 1.072bn, while the company recorded approximately CNY 156m of new goodwill impairment.

There is one important positive accounting feature. Aier generally defines each hospital as the smallest independently cash-generating asset group for impairment testing, rather than pooling a large number of hospitals into one broad national cash-generating unit. That makes cross-subsidization in impairment testing harder. The annual report’s sampled recoverable-value assumptions nevertheless require judgment: many hospital models use 2026–2030 forecasts, zero terminal revenue growth, and discount rates in roughly the mid-teens, with hospital-specific forecast revenue growth and profit margins.

The business mix itself explains why Aier is less defensive than the word “hospital” suggests. In 2025 refractive surgery contributed CNY 8.383bn, 37.5% of revenue, and optometry/vision services another CNY 5.788bn, 25.9%. Together they accounted for 63.4% of group revenue. Refractive gross margin was 55.0%; optometry gross margin was 51.9%. Cataract contributed CNY 3.478bn, 15.6%, at only 33.5% gross margin, while posterior-segment services produced CNY 1.573bn at 27.6% gross margin. Consumer-paid refractive and optometry therefore carry disproportionate economic weight.

This gives Aier two different cycles at once. Aging supports cataract, retinal disease and presbyopia-related care: China had about 310m people aged 60 or older at end-2024, 22% of the population, and about 220m aged 65 or older. Myopia remains widespread; the National Disease Control authority’s data cited by Aier put childhood/adolescent myopia at 51.9% in 2022. But refractive surgery is discretionary and concentrated among younger adults, so consumer confidence and cohort demographics matter.

Regulation has also become harder, not softer. The National Healthcare Security Administration’s 2026 nationwide “fly inspection” program explicitly names ophthalmology among 15 priority medical areas for anti-fraud review. The broader 2026–2030 supervisory plan expands inspection coverage and data-based screening, while the regulator said by July 2026 that first-half inspections had covered 2,926 designated medical institutions and pharmacies across 227 cities, identifying CNY 1.16bn of suspected improper fund use.

That enforcement backdrop matters when assessing the February 2026 psychiatric-hospital controversy. Investigative reporting linked Xiangyang Hengtaikang Hospital, one of the psychiatric hospitals discussed in the broader Hubei scandal, through an ownership chain to Aier Medical Investment Group and ultimately Aier founder Chen Bang. Aier’s clarification stated that Hengtaikang was not part of the listed Aier Eye consolidation perimeter, that it was a fourth-tier subsidiary of Aier Medical Investment and other investors, and that neither the listed company nor Aier Medical Investment participated in its day-to-day management.

The subsequent official Hubei investigation was serious: police opened fraud investigations involving personnel at psychiatric institutions, detained multiple suspects, and disciplinary authorities opened cases involving public officials. The cited official result did not identify listed Aier Eye Hospital or Chen Bang as a subject of those enforcement actions. I found no public exchange or regulator finding by 2026-08-15 establishing that Aier Eye itself committed medical-insurance fraud in this matter. That distinction is essential. The event is a governance and reputation issue for Aier because of the founder’s broader private healthcare ecosystem, but treating it as an established fraud finding against the listed ophthalmology group would exceed the evidence.

The stock has already undergone a profound narrative reset. The market once priced Aier as a near-frictionless private-healthcare compounder. Adjusted share-price data peaked above CNY 40 in 2021; the current CNY 8.71 price is more than 70% below that area. More important than the price decline is the valuation decline: current P/S is about 3.6 times and sits around the lowest few percent of its ten-year distribution according to Lixinger’s historical series; TTM P/E is about 24 times. The share traded CNY 8.71 on 2026-08-14, near the bottom of its CNY 7.82–13.95 trailing-52-week range.

The current bull/bear dispute is therefore sharper than “good company versus bad company.” Bulls see the largest eye-care platform in China, still-positive traffic growth, strong operating cash generation, Q1 earnings reacceleration and a valuation that has lost most of its historical glamour. Bears see mature domestic organic growth, an increasingly acquisition-dependent revenue line, CNY 9.5bn of net goodwill, a founder-controlled ecosystem that extends outside the listed perimeter, and a consumer-heavy service mix facing weaker demographics and discretionary spending.

My qualitative portrait is company in transition. Aier has moved from proving that private specialist hospitals can compound nationally, to proving that a very large installed network and acquisition ecosystem can still earn acceptable incremental returns after the easiest geographic white space has been filled. Historical quality is real. The central question for the next decade is whether incremental quality is as high as historical quality.

Company vertical history and financial review

Aier’s origins explain much of the later model. The listed company was incorporated in Changsha on 2003-01-24. By the 2009 IPO prospectus it already operated a multi-city network: the filing listed 17 hospitals and 2,040 employees, including 1,329 medical personnel. The early model was straightforward specialist-hospital replication: centralize brand, management and specialist expertise, then reproduce an ophthalmology hospital format across cities where public-hospital eye departments dominated supply.

The ownership architecture was founder-led from the beginning. Before the IPO, Chen Bang directly held 23.8% of Aier and indirectly controlled another 60% through Hunan Aier Investment. Li Li and other founding executives also held meaningful stakes. Shenzhen Fortune Venture Capital/Dachen entered in 2007 with a 3% strategic holding, partly to broaden the shareholder base before listing. The holding company that became Aier Medical Investment was established in 2007 and was itself controlled by Chen Bang.

Aier listed on the Shenzhen ChiNext on 2009-10-30, one of the first cohort of ChiNext companies. It issued 33.5m shares at CNY 28 each, raising CNY 938m gross. The IPO brought public capital to a model that already had enough operating proof to move beyond regional expansion.

The subsequent history divides naturally into four stages.

The first, from 2003 through the 2009 listing, was the proof-of-format stage. Aier demonstrated that a private specialist hospital could attract doctors, win patient trust and transplant a recognizable brand across provincial borders. The critical constraint was capital: every new hospital carries rent, equipment, renovation and staffing costs before patient traffic reaches scale. The listed entity initially bore that ramp risk itself. The IPO solved the immediate funding problem but not the structural drag from opening many immature hospitals simultaneously.

The second stage, roughly 2010–2014, was public-market-funded national expansion. Scale began to create real operating advantages: purchasing, doctor training, referrals, national advertising and management systems could be shared across hospitals. Yet the fixed-cost character of hospitals meant fast greenfield expansion could still dilute consolidated margins. That constraint set up the next institutional innovation.

Around 2014 Aier began using industrial M&A funds more systematically. Third-party capital could incubate new hospitals outside the listed company, with Aier branding or support, while Aier retained the option to acquire mature assets later. Contemporary analysis identifies this as a major break in Aier’s expansion model, and the company’s own later disclosures explicitly discuss independently owned Aier-branded hospitals invested in through industrial M&A funds.

The third stage, from roughly 2014 to 2021, was the model’s compounding phase. The acquisition-fund structure let Aier increase network density faster than a pure consolidated greenfield strategy would have allowed. It also changed the optics of growth: young hospitals’ early losses were increasingly separated from the listed P&L, while successful hospitals entered the consolidated accounts after some of the hardest ramp-up had already occurred. Investors rewarded the resulting combination of high reported growth, high returns on equity and nationwide network effects with a large multiple expansion.

Aier also began exporting the platform. It entered Hong Kong in 2017, subsequently bought the MING WANG eye center in the United States and acquired European ophthalmology group Clínica Baviera in 2018. In 2024 Clínica Baviera acquired the UK Optimax/Eye Hospitals Group, broadening Aier’s European footprint. Overseas revenue reached CNY 3.057bn in 2025, up 16.47%, or 13.7% of group revenue.

The fourth stage began around 2022 and is still underway: the network is much larger, domestic penetration is higher, consumer growth is softer, healthcare enforcement is stricter, and investors demand proof that acquisitions create economic value rather than merely accounting growth. The 2024 and 2025 acquisition waves show that the machine remains active. The 2024 annual report said Aier acquired 87 medical institutions during that year; one major May 2024 transaction involved 52 institutions for about CNY 1.344bn. In December 2025 it followed with the 39-institution CNY 963m transaction.

The same period produced the first clear financial warning. The company’s reported numbers show the shift directly:

† Calculated from prior-year company disclosures. ‡ Quarter-only ROE, not annualized.

Source: 《2025 年年度报告全文》 and 《2026 年第一季度报告》.

The business reason behind the table is more important than the table itself. Revenue did not collapse in 2024–2025; the old relationship between expansion and incremental earnings weakened. Adjusted profit fell in 2024 despite higher revenue, then barely grew in 2025. ROE fell almost four percentage points from 2023 to 2025. Q1 2026 partially reversed the profit trend, but a single quarter has not yet repaired the three-year return-on-capital trend.

The 2025 reported-profit decline also looks worse than underlying operations because adjusted attributable profit still rose 1.36%. Aier’s fourth quarter was exceptionally weak: Q4 revenue was CNY 4.869bn, attributable profit only CNY 126m and adjusted profit only CNY 21m. Seasonality, asset impairment and year-end charges therefore mattered materially. The correct conclusion is that 2025 underlying earnings were nearly flat, not that the core business shrank 9%.

Cash generation remains one of the strongest parts of the case. Operating cash flow was CNY 5.973bn in 2025 versus CNY 3.240bn attributable profit, a ratio of 1.84 times. The fully verified 2023–2025 aggregate ratio is about 1.65 times. The longer annual-report series also indicates operating cash flow has normally exceeded attributable earnings, although I regard a precise five-year ratio as approximate because the 2021–2022 cash-flow lines were not independently re-tabulated during this research pass.

Cash capex for property, equipment, intangibles and other long-term assets was CNY 2.093bn in 2025, up from CNY 1.830bn in 2024. Subtracting all capex from operating cash flow gives a conservative 2025 free-cash-flow proxy of CNY 3.880bn, a 4.8% yield on the current CNY 81.0bn equity value. That is better than the accounting-earnings yield implied by the roughly 24 times TTM P/E.

Maintenance capex is not separately disclosed. I estimate roughly 60% of 2025 cash capex, around CNY 1.25bn, as maintenance and the balance as expansion/upgrade capital. On that assumption, operating cash flow less maintenance capex is about CNY 4.72bn, equivalent to a 5.8% owner-cash-earnings yield and roughly 17 times current market value. Because this estimate is sensitive to the maintenance/growth split, the valuation later in this report uses the more conservative all-capex cash-flow figure as a cross-check rather than capitalizing the CNY 4.72bn figure at face value.

Specialty mix shows where margin pressure comes from:

Source: 《2025 年年度报告全文》; units converted from yuan to CNY billions.

Refractive and optometry remain the earnings engine because they combine faster growth with gross margins above 50%. Cataract barely grew and carried a gross margin roughly 22 percentage points below refractive surgery. Posterior-segment treatment is medically important but economically much thinner. A consolidated 6.5% revenue growth rate therefore hides a favorable mix shift toward refractive and optometry in 2025 even while total gross margin still declined.

That gross-margin result is a warning. Medical-services gross margin fell about one percentage point to 47.05%. Refractive margin was nearly stable, but cataract fell 1.24 percentage points, posterior segment 3.78 points and optometry 2.57 points. Volume growth alone is therefore insufficient; mix, procurement, doctor compensation, hospital maturity and consumer pricing all affect incremental profitability.

The balance sheet is where acquisition economics accumulate. Total assets rose 10.3% in 2025 to CNY 36.676bn, while attributable equity rose 6.1% to CNY 21.974bn. Net goodwill of CNY 9.486bn is equivalent to roughly 43% of attributable book equity. This does not create a near-term liquidity crisis, but it means a large portion of historical capital allocation is represented by a non-amortizing asset whose value depends on the future cash flows of acquired hospitals.

The December 2025 deal makes that mechanism visible:

Source data from 《关于收购亳州爱尔、连云港爱尔等 39 家机构部分股权的公告》 (“Announcement on Acquisition of Partial Equity Interests in Bozhou Aier, Lianyungang Aier and 39 Institutions”); valuation ratios are my calculations.

The 39-target purchase is a bet on margin maturation, not a purchase of already-cheap earnings.

Management’s rationale is internally coherent. Hospitals have high fixed costs; new hospitals often lose money until traffic matures; the 39 targets moved from a CNY 59.0m aggregate loss in 2024 to a CNY 20.25m nine-month profit in 2025; many were near the break-even inflection point. The question for shareholders is whether Aier paid for that inflection before enough of the upside was earned.

The implied hurdle is demanding. If annualized revenue of roughly CNY 784m grows 8% annually for five years and net margin reaches 12%, the cohort could earn roughly CNY 138m, close to a 10% earnings yield on the CNY 1.403bn appraised equity value. That is a plausible outcome, but it requires five years of both revenue compounding and a move from a 3.4% margin to 12%. A stall at a 5%–7% margin would produce much weaker returns.

Goodwill makes failed maturation visible with a lag. Gross goodwill rose from CNY 10.169bn at the start of 2025 to CNY 11.366bn at year-end after CNY 1.072bn of business-combination additions and foreign-exchange effects. The accumulated impairment reserve rose from about CNY 1.721bn to CNY 1.879bn; roughly CNY 156m was provided during 2025.

The December deal announcement itself warns that the transaction will create goodwill and that underperformance may lead to impairment. The final amount depends on the acquisition-date fair value of net assets. I cannot reliably isolate the exact goodwill created solely by the 39-target transaction from the CNY 1.072bn aggregate 2025 addition, because the annual-report total includes all business combinations during the year. Treating the full CNY 1.072bn as “39-hospital goodwill” would therefore be incorrect.

The impairment test is reasonably granular. The annual report states repeatedly that management identifies an individual hospital’s book assets as a cash-generating unit because the hospital is the smallest asset combination capable of independently generating cash flow. That prevents a profitable Shanghai or Changsha flagship from mechanically hiding the underperformance of a smaller county hospital in the same test.

The assumptions nevertheless leave meaningful model risk. Sampled hospital tests use multi-year revenue and net-margin forecasts, discount rates around 14%–16%, and generally zero terminal growth. Some hospitals are forecast to move from very low or negative margins to positive steady-state margins. That is exactly where an overly optimistic ramp assumption could postpone impairment.

A balance-level stress illustrates materiality without pretending to reproduce the auditors’ CGU calculations. A 10% write-down of current net goodwill would be about CNY 0.95bn, equivalent to 29% of FY2025 attributable profit. A 20% write-down would be about CNY 1.90bn, 59% of attributable profit. Those are analytical shocks, not predictions, and actual impairment would occur CGU by CGU.

The share-price history mirrors these business stages. Aier’s first decade as a listed company was priced as proof that private specialist healthcare could compound nationally; the M&A-fund era amplified the growth narrative and helped the stock reach its 2021 peak. Since then, slower domestic growth, healthcare-policy concerns, COVID-era disruptions, consumer weakness, goodwill scrutiny and the collapse of the “perpetual high-growth medical services” valuation regime have driven both earnings-estimate reductions and multiple contraction.

The current valuation center is radically different. A roughly 24 times TTM P/E is still not a distressed multiple, but it is a long way from the premium historically attached to Aier. Lixinger’s series places the current P/S near the bottom few percent of its ten-year range, with a ten-year median around 5.5 times versus roughly 3.6 times now. The market has shifted from paying for network expansion to demanding evidence of network productivity.

Business model, moat, industry and governance

Aier’s economic machine starts with patient acquisition. A refractive-surgery customer may arrive through brand awareness, a local hospital, online marketing or referral. A cataract or retinal patient is more likely to be influenced by local doctor reputation, insurance eligibility and proximity. An optometry customer can become a repeated user rather than a one-off surgical patient. A national network therefore creates value only if the brand and referral systems lower customer-acquisition cost and help keep doctors and patients within Aier’s system.

Hospital economics then create operating leverage. The company’s December acquisition filing identifies long-term rent amortization, renovations, large ophthalmic-equipment depreciation and fixed compensation for medical and management teams as major fixed costs. A hospital operating below mature utilization can lose money even with reasonable gross procedure economics. Once volume rises, those fixed costs spread over more procedures and margins can improve quickly.

That explains why the M&A funds exist. They are effectively external incubation capital for the most painful part of the hospital S-curve. For the listed company, this lowers consolidated ramp-up losses and permits faster network build-out. For outside fund investors, the model offers an eventual exit to Aier if hospitals mature. The risk is circularity: Aier’s brand and assistance help make the hospital saleable, and Aier is later the natural buyer. Transaction discipline therefore matters more than it would for acquisitions sourced entirely from unrelated sellers.

The moat has four components that I regard as real.

First is brand and medical trust. Eye surgery is high-consequence even when elective. A national reputation matters more than in low-acuity retail healthcare. Aier has compounded that brand through clinical scale, academic collaborations and a very large patient base. Its 2025 annual report describes research collaborations with Tongren Hospital, the University of Cologne, Shenzhen People’s Hospital and other institutions, alongside specialist guideline work.

Second is doctor and clinical-network density. A national chain can offer specialist career paths, patient referrals, training and research infrastructure that a single city hospital cannot easily reproduce. This is especially relevant outside top-tier cities, where recruiting respected ophthalmologists is often a bigger constraint than buying equipment.

Third is the tiered network. Provincial-capital hospitals can handle complex cases and build brand prestige; city and county hospitals widen catchment areas, perform routine procedures and refer complex cases upward. That produces a geographic referral structure rather than a collection of identical stores. The December 2025 acquisition is revealing: only Qinghai Aier was a provincial-capital institution; the rest were predominantly city- and county-level assets.

Fourth is capital and acquisition infrastructure. Aier has repeated the hospital incubation, acquisition and integration process for years. That accumulated operating knowledge is difficult for a new entrant to copy quickly. It becomes a genuine moat only when acquired-hospital returns exceed Aier’s cost of capital. Scale without returns is an empire, not a moat.

Aier’s strongest moat is the combination of brand, clinical talent and network density; the M&A architecture is an amplifier of that moat, not proof of it.

Several apparent moats are weaker. Switching costs are modest for many patients: someone comparing LASIK providers can choose another hospital. Ophthalmic technology is purchased from equipment and consumable vendors rather than monopolized by Aier. Local public hospitals retain formidable physician reputations. Pricing power therefore varies substantially by procedure and geography.

The consumer exposure is unusually important. Refractive plus optometry produced almost two-thirds of 2025 revenue. These services are less dependent on public insurance, which limits payer pressure, but they are more exposed to disposable income, employment confidence and younger-adult demographics. Cataract and retinal care benefit from aging but face more public-payer and reimbursement constraints.

This creates a portfolio effect. A recession or weak consumer-confidence period can hurt refractive conversion and premium lens/optometry spending while cataract demand remains medically necessary. Aging can lift medically necessary case volumes even while younger cohorts shrink. Aier therefore sits at the intersection of consumer, demographic and policy cycles rather than fitting cleanly into “defensive healthcare.”

China’s demographic backdrop remains favorable for age-related eye disease. At end-2024, 22% of the population was 60 or older and 15.6% was 65 or older. Cataract, diabetic retinopathy, age-related macular degeneration and presbyopia should all rise with that cohort. Children’s and adolescent myopia prevalence remains high. These figures establish durable demand without requiring a speculative private-sector “TAM” estimate.

The demand opportunity does not guarantee provider profit growth. Public hospitals compete aggressively for complex medical cases, while specialist private chains compete for refractive and optometry patients. Central procurement of ophthalmic consumables can lower acquisition costs but also forms part of a broader policy environment in which procedure prices, reimbursement and hospital behavior face tighter scrutiny. I have not modeled a new 2026 intraocular-lens procurement price shock because the retrieved source set does not give a clean province-by-province implementation update; that is preferable to attaching false precision to an already-established policy.

Medical-insurance enforcement is much clearer. NHSA’s 2026 inspection program explicitly includes ophthalmology as a priority. The regulator is expanding national coverage, data analytics and accountability through the 2026–2030 action plan. For Aier, the direct financial exposure is greatest in reimbursed specialties such as cataract and medically necessary disease treatment, while the indirect exposure is reputational across the whole network.

Governance deserves the same weight as operating strategy. Chen Bang remains the actual controller. The 2025 annual report states that he owns 79.99% of Aier Medical Investment Group, while Li Li owns 20.01%. Aier Medical Investment remains the listed company’s controlling shareholder; media coverage of the February 2026 clarification cited its listed-company holding at approximately 34.34%.

The parent-company relationship is broader than formal related-party accounting. Aier’s annual report discloses routine transactions with Aier Medical Investment and related entities, including small rents and service items. The 39-target acquisition itself was formally declared not to constitute a related-party transaction under applicable listing rules. Yet several sellers were healthcare investment funds embedded in the wider Aier incubation ecosystem. Legal related-party status and economic conflict risk are therefore different questions.

The partner plan is intended to align doctors and managers with hospital-level economics. The 2025 annual report says the company continued partial realization of its partner plan and describes long-term incentives as supporting development. This can improve retention and local entrepreneurship. It also means some subsidiary economics belong to minority shareholders rather than entirely to listed-company shareholders, so investors should focus on attributable earnings rather than consolidated hospital-level profit.

I have not reproduced a sufficiently reliable 2025 minority-profit line from the extracted filing pages to give a precise percentage of consolidated profit, and I will not manufacture one. That is one of the remaining disclosure-extraction blind spots for a refresh. The analytical treatment is conservative: all valuation work uses attributable earnings or equity cash-flow measures rather than total consolidated net income.

Controlling-shareholder share pledges are another governance variable. Market data showed total pledged shares across relevant holders of about 1.011bn shares, 10.87% of Aier’s total equity, as of 2026-08-14; Chen Bang also released a pledge on 139m shares in July. This does not by itself imply financial stress, but a sharp future increase would matter because the founder controls both the listed company and a substantial non-listed healthcare-investment ecosystem.

The psychiatric-hospital episode is best treated as a governance-boundary test. Investigative journalism established alleged misconduct at psychiatric hospitals in Hubei, and official investigations later led to criminal and disciplinary action involving multiple hospitals and officials. Aier established a factual corporate perimeter in its response: Xiangyang Hengtaikang was not a listed-company subsidiary, Aier Eye had no equity-control or operating-management relationship with Hunan Hengtaikang and its subsidiaries, and the parent investment group said it did not run the hospital day to day.

The residual governance concern is not direct listed-company legal liability established by this case. It is whether investors have enough visibility into the founder-controlled healthcare assets that sit near the Aier brand but outside the listed perimeter. The February market reaction—a decline of more than 3% on the first morning and roughly 7% over the immediate two-day period reported by financial media—shows that investors price that boundary as a trust variable.

Horizontal competitor analysis

Aier has ample direct competitors, so the relevant framework is Scenario C. The most useful listed domestic references are Huaxia Eye Hospital Group (华厦眼科, 301267.SHE), Purui Eye Hospital Group (普瑞眼科, 301239.SHE), He Eye Specialist Hospital Group (何氏眼科, 301103.SHE) and Hong Kong-listed Chaoju Eye Care (朝聚眼科, 2219.HK). Aier’s own 2022 financing materials used Huaxia, Purui and He Eye among its ophthalmology-service comparisons, confirming that these are operational rather than merely thematic peers.

Aier became the national platform. Its scale is in a different category: 2025 revenue was CNY 22.35bn and attributable profit CNY 3.24bn, while it operates a dense multi-tier domestic system plus overseas businesses. Its acquisition-fund infrastructure is more developed than those of the smaller listed chains. The benefit is network reach and cash generation; the cost is the largest absolute goodwill exposure and the greatest challenge separating acquired from organic growth.

Huaxia became the closest smaller national challenger. It has multi-regional hospital coverage and competes head-on in major ophthalmic procedures, but its scale and network breadth remain well below Aier. The valuation comparison is telling: around the research date Huaxia traded near CNY 15.88 with a TTM P/E of roughly 28.8 times and P/B around 2.45 times, versus Aier at roughly 24 times TTM earnings. Aier therefore no longer carries the obvious multiple premium one might expect from its scale leadership.

Purui illustrates the accounting contrast most clearly. Purui generated CNY 2.797bn of 2025 revenue, up 4.44%, but still lost roughly CNY 61m even after narrowing its loss. Its 2025 accounts carried about CNY 1.40bn of lease liabilities including current portions, reflecting the fixed-cost burden of a hospital network that bears more ramp-up economics directly on its own consolidated statements.

That does not automatically make Purui “worse” or Aier “better.” It highlights an accounting choice embedded in the business model. A chain that consolidates greenfield hospitals early shows more start-up losses in reported earnings. Aier’s fund-incubation system can show fewer of those losses, then pay an acquisition premium when hospitals mature. The economic comparison must therefore add acquisition capital and goodwill back into Aier’s growth equation rather than comparing headline margins mechanically.

He Eye occupies a more regional niche, historically centered on Northeast China and combining hospitals with optometry and eye-health/prevention networks. Industry data place it below Aier, Huaxia and Purui in revenue scale. Its smaller footprint reduces national-network advantages but also limits the complexity of Aier’s acquisition perimeter.

Chaoju is another useful regional contrast. Its northern-China concentration gives investors a cleaner view of regional eye-care economics but without Aier’s nationwide referral network or comparable acquisition machine. It is less useful as a direct valuation anchor because the listing currency and market are different, yet useful for judging whether national scale actually produces superior margins and growth.

The small set of verified comparable datapoints below is more useful than filling missing cells with secondary estimates:

† n/v means not independently verified to primary-source standard in this research pass. ‡ Search-result company data indicate roughly mid-single-digit growth; I do not use the figure in valuation. § Purui’s trailing earnings remained negative.

Sources: company filings and dated market data.

The table understates Aier’s structural lead. Aier is roughly eight times Purui’s 2025 revenue and generates billions of renminbi of annual cash flow while Purui is still working through fixed-cost ramp losses. That gap gives Aier purchasing power, brand reach, doctor-development resources and acquisition capacity that smaller peers cannot easily match.

The strongest horizontal challenge to Aier comes from a different direction: public tertiary hospitals plus regional private specialists. Complex retinal, glaucoma and difficult surgical cases often follow famous doctors rather than corporate brands. Aier can offset that through academic investment and its referral network, but it cannot monopolize clinical talent.

For consumer refractive surgery, competition is more commercial. Huaxia, Purui and strong local hospitals can compete on surgeon reputation, equipment, pricing and online customer acquisition. Because switching costs are low before treatment, a price war would hit Aier’s highest-margin business more directly than it would affect insured disease treatment.

Aier’s ecological niche is therefore “national specialist-care platform,” not simply “largest hospital chain.” It takes profit pools from fragmented local private clinics and, at the margin, from public-hospital ophthalmology departments in elective or service-sensitive procedures. Its own profit pool is most vulnerable to regional chains that reproduce high-quality elective surgery without bearing the corporate overhead or acquisition premiums of a nationwide system.

The comparison also changes how the current valuation should be read. Aier’s 24 times TTM P/E is below Huaxia’s roughly 29 times, while Purui cannot be valued sensibly on P/E. That discount can be justified if Aier’s organic growth is slower and goodwill/governance complexity warrants a penalty. It can converge upward if acquired-hospital returns improve and Q1’s earnings recovery persists.

Current fundamentals, valuation, risks and catalysts

The last four reported quarters tell a story of deceleration followed by partial stabilization. Q1–Q3 2025 each produced roughly CNY 1.0bn of attributable profit; Q4 dropped to CNY 126m. Full-year adjusted profit was essentially flat. Q1 2026 then restored double-digit adjusted-profit growth even though revenue remained in the mid-single digits.

The most constructive part of Q1 was operating leverage: attributable profit rose roughly twice as fast as revenue. The least constructive part was cash: operating cash flow fell 6.18%. A clean reacceleration would require both trends to persist through the first half—mid-single-digit or better organic demand, margin stabilization and cash growth resuming.

The market is currently trading four narratives simultaneously. First, the old 15%–25% growth assumption has disappeared. Second, investors are testing whether the Q1 profit recovery marks a bottom. Third, goodwill and acquisition-return questions have moved from footnotes into valuation. Fourth, the February governance episode reinforced a trust discount around the founder’s broader healthcare ecosystem. The CNY 8.71 share price near the bottom of the 52-week range suggests the market is not currently pricing a return to the 2015–2021 compounding regime.

One post-2025-results brokerage forecast expected 2026 revenue around CNY 24.4bn and attributable profit around CNY 3.7bn. That would imply roughly 9% revenue growth and mid-teens profit growth, materially better than 2025. I treat it as an analyst reference point, not company guidance or consensus.

The first expectation test arrives quickly: Aier’s 2026 interim report is scheduled for 2026-08-28. The most important number will not be headline revenue alone. Investors need domestic organic growth, refractive and optometry growth, hospital maturity, cash flow and any change in goodwill or impairment.

The historical valuation is optically compelling. At approximately 24 times trailing earnings and roughly 3.6 times sales, Aier sits near the bottom of its ten-year P/S history rather than near the 2021 euphoria. The low historical percentile is evidence of de-rating, not evidence of undervaluation. A business that has structurally moved from double-digit organic growth to low-single-digit organic growth deserves a lower multiple.

Current valuation is no longer heroic; whether it is cheap depends almost entirely on the normalized organic growth rate and the returns on acquired hospitals.

The cash-flow passthrough makes valuation less expensive than headline accounting P/E suggests. FY2025 OCF was 1.84 times attributable profit. All-capex free cash flow of about CNY 3.88bn gives a 4.8% yield; my estimated maintenance-only owner cash flow of roughly CNY 4.7bn gives a 5.8% yield. Because the maintenance-capex assumption is uncertain, I use CNY 3.9bn–4.5bn as a normalized cash-earnings starting band rather than the maximum estimate.

The valuation scenarios below combine P/E/owner-earnings multiples with cash-flow cross-checks. They do not assume Aier deserves its former premium simply because the share price has fallen.

These are valuation scenarios within a research framework, not investment advice. Inputs are my assumptions anchored to the latest filings and CNY 8.71 market price.

The conservative range looks low because it treats current 2025 earnings as close to mature and removes part of Aier’s historical quality premium. The optimistic range requires a genuine improvement in organic growth and acquisition margins, not just more acquisitions.

The most fragile base-case assumption is that the acquired-hospital cohorts can progress toward roughly 10%–12% net margins while domestic organic growth holds around 4%–6%. Reducing that incremental profit contribution to 70% of my base assumption cuts fair value to roughly CNY 8.1–8.6. At CNY 8.71 the stock would then already be slightly above the weakened base value.

The margin-of-safety test is harsher. Current price is 24%–34% above my CNY 6.5–7.0 conservative intrinsic-value range, so the margin of safety against the conservative case is zero.

A flat-earnings exercise reinforces that conclusion. FY2025 attributable EPS on the current share count is about CNY 0.35. If earnings remain flat for three years and the exit multiple normalizes to 20 times, the terminal price would be roughly CNY 7.0. Even adding roughly CNY 0.5–0.6 of cumulative dividends, the annualized return from CNY 8.71 would be around negative mid-single digits. China’s 10-year government-bond yield was 1.70% on 2026-08-14. On that normalized-multiple flat-earnings case, there is no margin of safety at this buy price.

If the market leaves the P/E unchanged at about 24 times, flat earnings would instead produce roughly the dividend yield, around 2%. That is only a small premium over the 1.70% sovereign yield for taking hospital-operating, goodwill and governance risk.

Margin-of-safety sufficiency verdict: none.

The first major permanent-capital risk is acquisition-return failure. I rate its probability medium-high and impact high. The observable indicator is the post-acquisition margin of 2024–2025 cohorts. A sustained margin below 5% several years after consolidation would imply that Aier paid for growth it did not receive. The transmission path is lower incremental ROIC, larger goodwill impairment, lower reported profit and a lower structural P/E.

Goodwill turns that risk from theoretical to measurable. Net goodwill is already 25.9% of assets. A CNY 0.95bn stress impairment, 10% of carrying goodwill, would absorb almost 30% of FY2025 attributable profit. A CNY 1.9bn stress would consume close to 60%. The probability of a system-wide 20% impairment in one year is low, but the impact is high; the indicator to watch is the number of hospital CGUs whose forecasts rely on double-digit revenue growth or sharp margin improvement despite weak local economics.

The second risk is consumer weakness in refractive and optometry. Probability is medium, impact high because these two categories account for 63.4% of revenue and carry the highest gross margins. A 5% revenue shortfall in these segments can have a disproportionate profit effect if fixed hospital and customer-acquisition costs do not fall at the same pace. The observable indicators are refractive volume/revenue, average ticket and optometry growth.

The third is healthcare-insurance enforcement. Probability of heightened audit activity is high because it is already policy; probability of a financially material Aier-specific sanction is lower and currently unproven. Impact would be high if multiple Aier hospitals lost reimbursement eligibility or faced major repayment claims. The immediate indicators are NHSA/provincial inspection notices, reimbursement suspensions, administrative penalties and disclosures of material repayments. Ophthalmology is explicitly within the 2026 fly-inspection focus.

The fourth is governance spillover from the founder-controlled non-listed ecosystem. Probability is medium and the direct earnings impact may be low, but the valuation impact can be high because healthcare depends heavily on trust. The psychiatric-hospital episode showed the transmission path: an issue outside the listed consolidation perimeter can still produce an immediate share-price reaction if investors view the ownership boundary as porous. The indicators are new regulatory findings involving founder-controlled healthcare entities, greater related-party transactions, or a rising pledge ratio.

The fifth risk is simple multiple compression. At 24 times earnings Aier is cheap relative to its own history but not cheap relative to a no-growth company. If attributable profit stays around CNY 3.2bn and the market concludes sustainable growth is only 2%–4%, a 15x–18x multiple would imply an equity value of roughly CNY 49bn–58bn, or approximately CNY 5.2–6.3 per share before considering future dividends. This is the main reason historical-percentile analysis alone cannot support a buy thesis.

Positive catalysts are straightforward. The August interim report could show that Q1’s earnings acceleration continued, operating cash flow caught up, and refractive/optometry maintained growth without further gross-margin deterioration. Evidence that 2024–2025 acquired hospitals are crossing from low-single-digit to high-single-digit margins would be more valuable than another large acquisition announcement. A smaller annual goodwill charge would also lower the market’s perception that acquisitions merely defer losses.

Overseas execution can become a second catalyst. Aier generated CNY 3.057bn abroad in 2025, up 16.47%, and continued expanding internationally. If overseas operations can grow faster than domestic business without requiring repeated premium-priced acquisitions, they could diversify both demographics and regulation.

Negative catalysts are the mirror image: a half-year revenue print that remains around 5% but with profit re-slipping; refractive growth below zero; weaker cash conversion; large hospital-specific goodwill impairments; or any Aier-specific NHSA enforcement action. A fresh acquisition at a high price-to-sales multiple before the prior cohorts show attractive margins would also reinforce the bear thesis.

My tracking dashboard uses analyst thresholds rather than management guidance:

The operating indicators should be pulled from CNINFO annual/interim reports and investor-relations materials; enforcement from NHSA and provincial medical-insurance authorities; pledge data from exchange disclosures; valuation from dated market data. The 2026-08-28 interim-report date is the first near-term checkpoint.

Cross-synthesis summary

Vertically, Aier has proven one capability beyond reasonable dispute: it can turn specialist ophthalmology from a collection of local doctor practices into a repeatable multi-city operating system. The proof is not the share price. It is the transformation from 17 hospitals at IPO into a nationwide and increasingly international network, the persistence of multi-billion-renminbi cash flow, and the ability to sustain more than CNY 22bn of annual revenue across multiple specialties.

That success was partly management skill and partly the era. China offered rising household income, unmet demand for better eye care, rapid myopia growth, population aging, policy support for social capital in healthcare and a fragmented provider market. Public equity then supplied capital, while the industrial-fund model solved the problem of having too many loss-making hospitals inside the listed entity at once.

Management’s real innovation was financial as much as medical: separate incubation from consolidation. That structure accelerated geographic expansion and made reported earnings smoother. It also means the past decade’s ROE cannot be read exactly like the ROE of a company that funded every start-up loss itself. Some capital risk and early losses sat in external funds before assets entered the listed balance sheet.

The structure remains legal and economically understandable. The problem is that it makes incremental return on acquisition capital the critical metric, while Aier does not give shareholders a clean vintage-by-vintage ROIC table. Revenue growth therefore becomes increasingly ambiguous precisely when the network becomes larger and more acquisition-heavy.

The 39-target deal shows why the debate has changed. These were not obviously failing assets when Aier bought them. Their aggregate result had moved from a CNY 59m loss to a CNY 20m nine-month profit, and management was buying near the claimed break-even inflection. That is the ideal point in the Aier playbook.

Yet the appraisal valued them at CNY 1.403bn, about 52 times annualized nine-month earnings. The return is attractive only if the inflection continues. A fivefold increase in profit from the annualized starting level would be required to earn about 10% on the appraised equity value. A hospital chain can plausibly achieve that through fixed-cost leverage; it is not an automatic outcome.

This is where Aier’s 2026 valuation becomes interesting. Investors no longer pay as though every acquired hospital will succeed. At about 24 times trailing earnings and a ten-year-low-area P/S, the stock has shed most of the multiple associated with the former perpetual-growth narrative.

The de-rating is rational. The 2024 adjusted-profit decline established that Aier had left its previous earnings regime. In 2025 adjusted profit grew only 1.36%. Q1 2026 showed a welcome rebound to 10.92% adjusted-profit growth, but part of the group’s revenue increase can plausibly come from consolidation scope. The company has not yet shown enough same-store disclosure to prove that domestic organic growth has returned to high single digits.

Horizontally, Aier still has the best strategic position among listed Chinese ophthalmology chains. Purui’s 2025 loss is a reminder of how punishing hospital ramp-up can be when fixed costs sit directly in consolidated accounts. Huaxia is smaller and trades at a higher earnings multiple. He Eye remains more regional. Aier therefore deserves some quality premium for network density, cash generation and operating experience.

That advantage is durable but not limitless. Refractive surgery has low switching costs before treatment. A respected surgeon at Huaxia, Purui or a public hospital can take a patient without dismantling Aier’s network. The national brand helps customer acquisition; it does not create software-like lock-in.

The highest-quality part of Aier today is cash generation. CNY 5.97bn of 2025 operating cash flow against CNY 3.24bn of attributable earnings provides genuine protection against the view that all accounting profit is fictitious acquisition output. Even after CNY 2.09bn of long-term-asset capex, the group generated roughly CNY 3.88bn of cash.

The lowest-quality part is the opacity around incremental returns. CNY 9.49bn of net goodwill is not merely an accounting footnote; it is the cumulative residue of prices paid above identifiable net assets. A hospital-level impairment approach is relatively disciplined, but the models still depend on future growth and margin assumptions.

Goodwill is now a capital-allocation scorecard for the next phase of Aier’s history.

If annual impairment stays around CNY 0.1bn–0.3bn while acquisition cohorts mature to high-single- or low-double-digit margins, the balance will look manageable. If impairment moves toward CNY 1bn annually and newer hospitals remain at low-single-digit margins, the entire historical acquisition premium deserves to be reconsidered.

Governance deserves a similar conditional judgment. The February 2026 psychiatric-hospital matter did not establish wrongdoing by listed Aier Eye. Official investigations targeted misconduct across psychiatric institutions and public officials, while Aier stated that the relevant hospital sat outside its listed-company perimeter. Those are the facts available at the base date.

The investment implication is still negative at the margin because the event exposed how much the founder’s non-listed healthcare empire matters to perception of the listed company. The appropriate governance discount is therefore for complexity and reputation spillover, not for an unproven allegation of listed-company fraud.

Over one year, three variables dominate: organic versus acquisition revenue growth, gross/net margin normalization, and cash conversion. The August interim report will provide the first evidence. If attributable profit remains double-digit while OCF recovers and specialty margins stabilize, the Q1 rebound gains credibility. If profit growth slips back toward zero, the stock’s low historical valuation may simply reflect a lower new earnings regime.

Over three years, acquisition vintages matter more than quarterly growth. The 52-hospital 2024 transaction and 39-institution 2025 transaction should be earning materially more than at entry. The most useful disclosure Aier could give investors would be vintage revenue, operating profit, purchase consideration and goodwill for acquired hospitals at years one, three and five. Until that exists, shareholders must infer acquisition returns indirectly.

Over five years, the question becomes whether Aier can replace geographic roll-out with productivity. A mature nationwide network can still compound if each hospital increases patient density, adds higher-value specialties, deepens optometry relationships and refers complex cases efficiently. Overseas operations provide another growth route. But an acquisition-driven hospital chain cannot create enduring value simply by increasing the number of consolidated entities.

The market may currently be misjudging two things in opposite directions. Bears may underweight Aier’s real cash generation and the possibility that Q1 2026 marks the beginning of margin recovery. Bulls may still overstate organic growth by reading consolidated revenue as same-store revenue. Both errors can coexist.

At CNY 8.71, the stock is no longer priced for perfection. It is also not priced for failure. My base intrinsic range of CNY 9–10 assumes that Aier can hold mid-single-digit underlying growth, improve acquisition cohorts and maintain strong cash conversion. That is close enough to current price that there is little reason to accept major uncertainty without a discount.

The conservative CNY 6.5–7.0 value is more revealing. Current price is well above it. For a new shareholder seeking a genuine margin of safety against lower growth, acquisition disappointment and a lower terminal multiple, patience has value.

A better investment setup would arise in one of two ways. Price could fall into the CNY 5.0–5.5 area while the underlying business and regulatory position remain intact. Alternatively, fundamentals could improve enough to move the conservative value upward: two consecutive reporting periods with estimated organic growth above roughly 6%, stable or improving group gross margin, TTM OCF/profit above 1.3 times, annual goodwill impairment below CNY 0.3bn and clear evidence that recent acquired hospitals are progressing toward high-single-digit margins.

The thesis should be overturned in the negative direction if acquired-hospital margins remain below 5% three to five years after purchase, net goodwill exceeds 30% of total assets because acquisitions continue faster than cash earnings, annual impairment exceeds roughly CNY 0.8bn without a one-off explanation, or a material regulatory finding establishes systemic reimbursement misconduct within the listed Aier network.

Core bull reasons:

• Q1 2026 attributable and adjusted profit grew 12.46% and 10.92%, respectively, after FY2025 adjusted profit had grown only 1.36%, providing the first evidence of earnings reacceleration.
• FY2025 operating cash flow of CNY 5.97bn was 1.84 times attributable profit, and all-capex free cash flow was roughly CNY 3.88bn, giving Aier much better cash conversion than the headline P/E alone suggests.
• Refractive and optometry revenue still grew 10.26% and 9.64% in 2025 and together generated 63.4% of group revenue at gross margins above 50%.
• Aier’s current roughly 3.6 times P/S sits near the bottom of its ten-year history, so the stock no longer embeds the valuation assumptions of the 2021 growth narrative.

Core bear reasons:

• Adjusted profit fell 11.82% in 2024 and grew only 1.36% in 2025, showing that the growth-model strain began before the reported FY2025 profit decline.
• The 39 acquired institutions were valued at CNY 1.403bn despite annualized nine-month 2025 profit of only about CNY 27m, implying roughly 52 times current earnings and requiring a large profit ramp to earn an acceptable return.
• Net goodwill of CNY 9.49bn equals 25.9% of total assets, leaving earnings and book quality sensitive to hospital-level forecast assumptions.
• The annual report does not provide a clean same-store series, so reported mid-single-digit growth cannot be cleanly separated from newly consolidated hospitals and overseas acquisitions.
• NHSA’s 2026 inspection program explicitly prioritizes ophthalmology, while the founder’s connection to non-listed healthcare assets adds reputation and governance spillover even where listed-company liability is not established.

Pre-mortem.

Script one: by 2027–2028 weak discretionary consumption and more aggressive pricing by Huaxia, Purui and strong local refractive centers push Aier’s refractive revenue from high-single-digit growth to a 5% decline. Refractive gross margin falls from 55% to below 48% as customer-acquisition spending and surgeon compensation do not fall with price. Group attributable profit remains near CNY 3.2bn for three years. Investors then value Aier at 16 times rather than 24 times earnings, implying roughly CNY 5.5 per share. A simultaneous CNY 0.8bn–1.0bn goodwill charge could push the share price toward CNY 4.5–5.0, roughly a 45%–50% loss from the current level.

Script two: the 2024–2025 acquisition cohorts never mature beyond a 4%–6% net margin because lower-tier-city patient growth is weaker than the appraisal models assumed. By 2028 several hospital CGUs fail impairment testing; Aier records CNY 1.5bn of cumulative goodwill impairment while NHSA audits cause temporary reimbursement suspensions at several insured-service hospitals. Attributable normalized earnings fall toward CNY 2.7bn, and the market assigns a 15 times P/E because acquisition growth is no longer trusted. The implied equity value is around CNY 40bn, about CNY 4.3 per share, roughly half the present price.

The final research conclusion is that Aier remains a better business than the share-price chart implies, but the old investment thesis no longer fits. The company has proved a national specialist-hospital platform, a strong brand and unusually good cash-generation capacity. The 2024–2025 earnings slowdown has not destroyed those assets. It has exposed the harder question: the return on the next yuan of acquisition capital.

At CNY 8.71, investors are no longer being asked to pay a premium-growth multiple, but they are still being asked to believe that recent acquisitions mature, goodwill remains recoverable and domestic organic growth settles above stagnation. My base valuation supports the current price; my conservative case does not provide enough downside protection. Existing shareholders can justify holding while the next two reporting periods test Q1’s recovery. A new position has a more attractive asymmetry closer to CNY 5.0–5.5, unless operating evidence improves enough to raise the conservative value first.

The evidence that would change my mind positively is concrete: sustained organic growth above roughly 6%, stable 47%-area medical gross margin, acquired-hospital margins moving toward 8%–12%, annual goodwill impairment below CNY 0.3bn and continued OCF/net-income conversion above 1.3 times. A material Aier-specific insurance-fraud finding, repeated impairment above CNY 0.8bn, or acquired hospitals failing to clear a 5% margin several years after consolidation would move the judgment in the opposite direction.

【Company-profile scores】

• Fundamental quality: medium
• Growth: medium
• Moat: medium
• Financial soundness: medium
• Management credibility: medium
• Valuation attractiveness: medium
• Risk level: high
• Suitable investor type: long-term growth

【Investment rating】

• Rating: Hold
• One-line thesis: Cash generation and network quality support current value, but acquisition returns, goodwill and low organic-growth visibility leave no conservative margin of safety.
• Ideal buy price: see the required standalone line below.
• Acceptable hold price: CNY 8.0–11.0
• Clearly overvalued price: CNY 15.5–17.0
• Current-price classification: acceptable hold
• Whether to wait for a better price: yes. For a new position, I would wait for CNY 5.0–5.5 unless acquired-hospital margins, organic growth and impairment evidence raise the conservative valuation. The opportunity cost is missing a Q1-led reacceleration that could move the stock toward the CNY 9–10 base value before such a price appears.
• Target holding horizon: 3–5 years
• Expected annualized return: conservative approximately 0%–4%; base approximately 8%–12%; optimistic approximately 18%–24%, including modest dividends and assuming the scenario’s terminal economics are achieved.
• Max-loss risk: approximately 50%–55% in the pre-mortem case, triggered by earnings falling toward CNY 2.7bn, CNY 1bn-plus cumulative impairment and a 15x terminal P/E.
• Reassessment-trigger signals: estimated organic revenue growth below 3% for two reporting periods; medical gross margin below 45.5%; annual goodwill impairment above CNY 0.8bn; recent acquisition vintages still below 5% net margin after 3–5 years; or a material regulator finding of systemic improper medical-insurance use within the listed group.

【Ideal Buy Price】5.0–5.5 CNY Basis: at least a 20% discount to the CNY 6.5–7.0 conservative intrinsic-value range, with no new material regulatory finding and no evidence that acquisition economics have structurally deteriorated.

【Valuation Range】

• current: 8.71 (close as of 2026-08-14)
• bear (conservative · ideal buy zone): [5.0, 5.5]
• base (fair · acceptable hold zone): [8.0, 11.0]
• bull (optimistic · above the clearly-overvalued line): [15.5, 17.0]

Research uncertainties. Five blind spots remain material. First, Aier does not disclose a complete same-store hospital series, so the 3%–5% organic-growth estimate is an analytical range rather than a reported KPI. Second, the exact goodwill created solely by the December 2025 39-institution transaction cannot be separated reliably from the CNY 1.072bn total 2025 business-combination additions in the extracted disclosure. Third, a clean 2025 minority-profit percentage was not reconstructed to primary-source standard, so valuation uses attributable earnings rather than trying to estimate minority leakage. Fourth, peer market data are less complete than Aier’s and are used directionally, not to force a peer-average target multiple. Fifth, the 2026 interim report had not been released by the 2026-08-15 research base date; it is scheduled for 2026-08-28 and could materially change the near-term earnings interpretation.

Primary source stack. The central company documents are 《爱尔眼科医院集团股份有限公司 2025 年年度报告全文》 (“2025 Annual Report”), 《爱尔眼科医院集团股份有限公司 2026 年第一季度报告》 (“Q1 2026 Report”), and 《关于收购亳州爱尔、连云港爱尔等 39 家机构部分股权的公告》 (“Announcement on Acquisition of Partial Equity Interests in Bozhou Aier, Lianyungang Aier and 39 Institutions”). The historical ownership and IPO analysis uses 《首次公开发行股票招股说明书》 (“Initial Public Offering Prospectus”). Regulatory analysis uses the National Healthcare Security Administration’s 2026 fund-supervision notice, 2026 fly-inspection launch and 2026–2030 supervision action plan. The psychiatric-hospital section distinguishes investigative reporting from the later official Hubei enforcement announcement and Aier’s own clarification. Current market pricing is dated to 2026-08-14, and the sovereign-rate comparison uses the Ministry of Finance/ChinaBond government yield curve for the same date.

Other tickers mentioned

• 301267.SHE — Huaxia Eye Hospital Group, the closest smaller A-share national ophthalmology-chain comparator.
• 301239.SHE — Purui Eye Hospital Group, useful for observing the fixed-cost burden of a more directly consolidated hospital-expansion model.
• 301103.SHE — He Eye Specialist Hospital Group, a smaller regional ophthalmology and optometry network.
• 2219.HK — Chaoju Eye Care, a northern-China regional eye-care chain used as a geographic and operating-model reference.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.